CRVO CervoMed Inc.: institutional ownership and insider trading
41 funds reported holding $8.49M of CervoMed Inc. in their latest 13F filings; in Q2 2026 funds net sold $69.5K, with 7 new positions and 5 funds selling out; over the last 12 months insiders bought $3.74M and sold $0 on the open market; over its last four quarters it reported revenue of $331K and net income of −$30.4M.
CRVO revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$6.57M
- Quarter ended Mar 31, 2026: revenue $0, net income −$7.96M
- Quarter ended Dec 31, 2025: revenue $8.73K, net income −$8.09M
- Quarter ended Sep 30, 2025: revenue $323K, net income −$7.73M
Largest institutional holders of CRVO
- VANGUARD GROUP INC — $2.80M
- Woodline Partners LP — $2.14M
- VANGUARD CAPITAL MANAGEMENT LLC — $980K
- SABBY MANAGEMENT, LLC — $772K
- GEODE CAPITAL MANAGEMENT, LLC — $208K
- BlackRock, Inc. (BLK) — $167K
- AVANTAX ADVISORY SERVICES, INC. — $164K
- Byrne Asset Management LLC — $147K
- VANGUARD FIDUCIARY TRUST CO — $112K
- CITIZENS FINANCIAL GROUP INC/RI (CFG, CFG-PE, CFG-PH, CFG-PI) — $111K
Recent CRVO insider trades
- Jun 11, 2026: Boger Joshua S bought 955,414 shares ($3.00M)
- Nov 18, 2025: Elder William Robert bought 3,500 shares ($29.3K)
- Nov 18, 2025: Winton Matthew bought 5,000 shares ($41.4K)
- Nov 17, 2025: Alam John J bought 21,600 shares ($183K)
5%+ owners
- BOGER JOSHUA S: 20.0% (Schedule 13D/A, filed Jun 15, 2026)
- Armistice Capital, LLC: 9.5% (Schedule 13G, filed Aug 14, 2026)
- RA Capital Management, L.P.: 8.6% (Schedule 13G/A, filed Aug 14, 2026)
- Woodline Partners LP: 5.1% (Schedule 13G, filed Aug 14, 2026)
Who owns the most CRVO stock?
The largest institutional holders of CervoMed Inc. in the latest 13F filings are VANGUARD GROUP INC ($2.80M), Woodline Partners LP ($2.14M), VANGUARD CAPITAL MANAGEMENT LLC ($980K).
Are insiders buying or selling CRVO?
Over the last 12 months insiders bought $3.74M and sold $0 of CervoMed Inc. stock on the open market (SEC Form 4).
What was CRVO's revenue last quarter?
CervoMed Inc. reported revenue of $0 for the quarter ended June 30, 2026, with net income of −$6.57M.